Jessica Noche, PhD, a postdoctoral scholar and REMIND co-chair recently published an article in the Journal of Neuroscience with UCI MIND faculty, Craig Stark, PhD, and Elizabeth Head, PhD, on the importance of playtime and socialization to increase regional brain size in aging beagles. Read their article and the summary of the study in Health Day
Read More
As we celebrate Women's History Month this March, we also find ourselves at a historic moment in scientific inquiry for women’s health research. Today, nearly two-thirds of Americans with Alzheimer’s disease are women, but the underlying cause of this sex disparity is still poorly understood. For decades, research focusing on women's health has been inadequate, with a mere 0.5% of all neuroimaging studies conducted over the past 25 years focusing on women's health. The potential to reach new heights in our understanding of the brain, especially today in the era of “big data” and artificial intelligence, is promising, but requires…
Read More
Ahmad Sajjadi, MD, PhD Ahmad Sajjadi, MD, PhD, UCI Neurologist and UCI MIND faculty member, was quoted in Healthline regarding the recent announcement by FDA to delay the decision to approve Eli Lilly's amyloid targeting drug, donanemab. Click here to read the article.
Read More
Tianchen Qian, PhD Ahmad Sajjadi, MD, PhD UCI MIND faculty member and UCI Neurologist, Ahmad Sajjadi, MD, PhD, awarded UCI Institute for Precision Health Pilot Award. Dr. Sajjadi will work with Tianchen Qian, PhD, a REC trainee and assistant professor of Statistics at UCI to study early detection of AD using deep machine learning. For a description of the project and to see other awarded projects, click here.
Read More
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab had been expected before the end of this month. Though data for donanemab’s ability to lower brain amyloid levels are convincing, the FDA had opted not to grant accelerated approval to the drug, citing limited safety data. This contrasted the agency’s decisions for two other amyloid-lowering drugs, aducanumab and lecanemab…
Read More
Message from the Director Dear Friends of UCI MIND, Happy New Year! We hope that 2024 is off to a positive start for you. As we embark upon a new year, UCI MIND and the field of Alzheimer’s disease and related dementias (ADRD) research are abuzz with excitement about progress made and opportunities to further advance our field. At the end of 2023, we held our annual signature fundraising event, the December to Remember Gala. We honored Lauren Miller Rogen and Seth Rogen, the founders of Hilarity for Charity (HFC) and our partners in a program to mentor and inspire…
Read More
Ahmad Sajjadi, MD, PhD, a UCI Neurologist and UCI MIND faculty member was interviewed live on NBC Los Angeles about the recent announcement that talk show host Wendy Williams has been diagnosed with frontotemporal dementia (FTD). Watch the interviews here: 4pm and 7pm broadcasts
Read More
Amyloid PET scan The LA Times recently published a fairly negative appraisal of the construct of preclinical Alzheimer’s disease (AD). The article described the recent effort by an international committee to update diagnostic criteria that date back to 1984, updated in 2011 and again in 2018. The most recent updates have been presented at meetings and published online and have indeed been the source of debate and disagreement in the field. But the LA Times article goes quite a bit further, essentially asking if one particular aspect of the criteria—the definition of preclinical AD—exists mainly to benefit pharmaceutical and medical…
Read More
Jessica Rinaldi/The Boston Globe Biogen, the maker of aducanumab has announced that it will terminate the Phase 4 trial required by the FDA for aducanumab, the monoclonal antibody against beta amyloid that received accelerated approval in 2021. The company is also halting production of the compound and relinquishing ownership rights to the original developer, Neurimmune. Accelerated approval was based on the demonstration in multiple studies that treatment with aducanumab could lower brain amyloid in people with Alzheimer’s disease. But two Phase 3 trials gave contrasting results about aducanumab’s efficacy, preventing the FDA from granting full clinical approval for the medication.…
Read More
The medications have not been widely tested in Black people with the disease, underscoring stark — and persistent — disparities Robert Williford, 67, receives a dose of Leqembi at Abington Neurological Associates in Abington, Pa. (Hannah Yoon for The Washington Post) ABINGTON, Pa. — Wrapped in a purple blanket, Robert Williford settles into a quiet corner of a bustling neurology clinic, an IV line delivering a colorless liquid into his left arm. The 67-year-old, who has early Alzheimer’s disease, is getting his initial dose of Leqembi. The drug is the first to clearly slow the fatal neurodegenerative ailment that afflicts 6.7…
Read More
